| Year |
Citation |
Score |
| 2022 |
Le Roux Ö, Pershing NLK, Kaltenbrun E, Newman NJ, Everitt JI, Baldelli E, Pierobon M, Petricoin EF, Counter CM. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis. Elife. 11. PMID 36069770 DOI: 10.7554/eLife.75715 |
0.314 |
|
| 2021 |
Li S, Counter CM. Signaling levels mold the RAS mutation tropism of urethane. Elife. 10. PMID 33998997 DOI: 10.7554/eLife.67172 |
0.301 |
|
| 2020 |
Li S, MacAlpine DM, Counter CM. Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nature Communications. 11: 1800. PMID 32286309 DOI: 10.1038/S41467-020-15660-8 |
0.377 |
|
| 2020 |
Adhikari H, Kattan W, Hancock JF, Counter CM. Abstract 1085: Interrogating the RAS interactome identifies EFR3A as a novel enhancer of RAS oncogenesis Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1085 |
0.308 |
|
| 2018 |
Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nature Reviews. Cancer. PMID 30420765 DOI: 10.1038/S41568-018-0076-6 |
0.406 |
|
| 2018 |
Fu J, Dang Y, Counter C, Liu Y. Codon usage regulates human KRAS expression at both transcriptional and translational levels. The Journal of Biological Chemistry. PMID 30275015 DOI: 10.1074/Jbc.Ra118.004908 |
0.427 |
|
| 2018 |
Adhikari H, Counter CM. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nature Communications. 9: 3646. PMID 30194290 DOI: 10.1038/S41467-018-05692-6 |
0.449 |
|
| 2018 |
Xu M, Casio M, Range DE, Sosa JA, Counter CM. Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30065097 DOI: 10.1158/1078-0432.Ccr-17-3705 |
0.388 |
|
| 2018 |
Kabiri Z, Greicius G, Zaribafzadeh H, Hemmerich A, Counter CM, Virshup DM. Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. The Journal of Clinical Investigation. PMID 30059017 DOI: 10.1172/Jci99325 |
0.362 |
|
| 2018 |
Sasine JP, Himburg HA, Termini CM, Roos M, Tran E, Zhao L, Kan J, Li M, Zhang Y, de Barros SC, Rao DS, Counter CM, Chute JP. Wild-type Kras expands and exhausts hematopoietic stem cells. Jci Insight. 3. PMID 29875320 DOI: 10.1172/Jci.Insight.98197 |
0.374 |
|
| 2017 |
Counter CM, Crowe MS, Greenberg DN, Brady DC. Copper Chelation Inhibits BRAFV600E-driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. Cancer Research. PMID 28986383 DOI: 10.1158/0008-5472.Can-16-1190 |
0.345 |
|
| 2017 |
Anderson GR, Winter PS, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Ali M, ... ... Counter CM, et al. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Reports. 20: 999-1015. PMID 28746882 DOI: 10.1016/J.Celrep.2017.07.006 |
0.355 |
|
| 2017 |
Ali M, Kaltenbrun E, Anderson GR, Stephens SJ, Arena S, Bardelli A, Counter CM, Wood KC. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nature Communications. 8: 15617. PMID 28593995 DOI: 10.1038/Ncomms15617 |
0.321 |
|
| 2017 |
Xu M, Range D, Sosa JA, Counter C. Copper chelation as targeted therapy in a genetic mouse model of oncogenic BRAF-driven thyroid cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E23148 |
0.36 |
|
| 2017 |
Pershing NLK, Lampson BL, Counter CM. Abstract IA14: Rare codons capacitate Kras-driven de novo tumorigenesis Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-Ia14 |
0.395 |
|
| 2016 |
Weyandt JD, Carney JM, Pavlisko EN, Xu M, Counter CM. Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice. Plos One. 11: e0167205. PMID 27911940 DOI: 10.1371/Journal.Pone.0167205 |
0.355 |
|
| 2016 |
Pershing NL, Yang CJ, Xu M, Counter CM. Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. Oncotarget. PMID 27285753 DOI: 10.18632/Oncotarget.9874 |
0.339 |
|
| 2015 |
Counter C. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis. Redox Biology. 5: 417. PMID 28162280 DOI: 10.1016/J.Redox.2015.09.023 |
0.413 |
|
| 2015 |
Weyandt JD, Lampson BL, Tang S, Mastrodomenico M, Cardona DM, Counter CM. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer. Plos One. 10: e0140253. PMID 26452271 DOI: 10.1371/Journal.Pone.0140253 |
0.426 |
|
| 2015 |
Schook LB, Collares TV, Hu W, Liang Y, Rodrigues FM, Rund LA, Schachtschneider KM, Seixas FK, Singh K, Wells KD, Walters EM, Prather RS, Counter CM. A Genetic Porcine Model of Cancer. Plos One. 10: e0128864. PMID 26132737 DOI: 10.1371/Journal.Pone.0128864 |
0.428 |
|
| 2015 |
Huang L, Counter CM. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S. Plos One. 10: e0123918. PMID 25902334 DOI: 10.1371/Journal.Pone.0123918 |
0.438 |
|
| 2015 |
Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, Counter CM, Kashatus DF. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Molecular Cell. 57: 537-51. PMID 25658205 DOI: 10.1016/J.Molcel.2015.01.002 |
0.389 |
|
| 2015 |
Pershing NL, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM, Counter CM. Rare codons capacitate Kras-driven de novo tumorigenesis. The Journal of Clinical Investigation. 125: 222-33. PMID 25437878 DOI: 10.1172/Jci77627 |
0.393 |
|
| 2014 |
Huang L, Carney J, Cardona DM, Counter CM. Decreased tumorigenesis in mice with a Kras point mutation at C118. Nature Communications. 5: 5410. PMID 25394415 DOI: 10.1038/Ncomms6410 |
0.365 |
|
| 2014 |
Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, Counter CM. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 509: 492-6. PMID 24717435 DOI: 10.1038/Nature13180 |
0.375 |
|
| 2014 |
Brady D, Crowe M, Turski M, Hobbs A, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell S, Thiele D, Counter C. Abstract IA09: Copper is required for oncogenic BRAF signaling and tumorigenesis Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Ia09 |
0.392 |
|
| 2014 |
Pershing NL, Lampson B, Counter C. Abstract A52: KRAS: The Rarefied Ras Oncogene Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A52 |
0.441 |
|
| 2014 |
Rund LA, Collares T, Seixas F, Begnini K, Counter CM, Schook LB. Abstract 69: Characterization of an inducible transgenic p53/Kras oncopig model for cancer Cancer Research. 74: 69-69. DOI: 10.1158/1538-7445.Am2014-69 |
0.427 |
|
| 2014 |
Huang L, Counter CM. Abstract 5250: The effect of introducing a C118S mutation into the endogenous Kras gene on early tumorigenesis Cancer Research. 74: 5250-5250. DOI: 10.1158/1538-7445.Am2014-5250 |
0.365 |
|
| 2014 |
Crowe MS, Counter CM. Abstract 4447: Generation of a conditional S194A mutant RalA allele in mice Cancer Research. 74: 4447-4447. DOI: 10.1158/1538-7445.Am2014-4447 |
0.42 |
|
| 2014 |
Brady DC, Crowe MS, Turski ML, Hobbs GA, Chaikuad A, Knapp S, Campbell SL, Thiele DJ, Counter CM. Abstract 4427: Copper is required for oncogenic BRAF signaling and tumorigenesis Molecular and Cellular Biology. 74: 4427-4427. DOI: 10.1158/1538-7445.Am2014-4427 |
0.388 |
|
| 2014 |
Weyandt JD, Counter CM. Abstract 4426: Tumor suppressive effects of wild-type Hras on oncogenic Kras-driven pancreatic tumorigenesis Cancer Research. 74: 4426-4426. DOI: 10.1158/1538-7445.Am2014-4426 |
0.443 |
|
| 2013 |
Yang S, Counter CM. Cell cycle regulated phosphorylation of the telomere-associated protein TIN2. Plos One. 8: e71697. PMID 23977114 DOI: 10.1371/Journal.Pone.0071697 |
0.335 |
|
| 2013 |
Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM. Rare codons regulate KRas oncogenesis. Current Biology : Cb. 23: 70-5. PMID 23246410 DOI: 10.1016/J.Cub.2012.11.031 |
0.417 |
|
| 2013 |
Rodrigues FM, Hu W, Rund L, Liang Y, Counter C, Schook L. Abstract 1573: An inducible transgenic porcine model for human cancer. Cancer Research. 73: 1573-1573. DOI: 10.1158/1538-7445.Am2013-1573 |
0.431 |
|
| 2012 |
Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM, Counter CM. Targeting eNOS in pancreatic cancer. Cancer Research. 72: 4472-82. PMID 22738914 DOI: 10.1158/0008-5472.Can-12-0057 |
0.333 |
|
| 2012 |
Yonekawa T, Yang S, Counter CM. PinX1 localizes to telomeres and stabilizes TRF1 at mitosis. Molecular and Cellular Biology. 32: 1387-95. PMID 22331467 DOI: 10.1128/Mcb.05641-11 |
0.372 |
|
| 2011 |
Kashatus DF, Counter CM. Breaking up is hard to do: RalA, mitochondrial fission and cancer. Small Gtpases. 2: 329-333. PMID 22545232 DOI: 10.4161/Sgtp.18284 |
0.394 |
|
| 2011 |
Barrientos KS, Lampson BL, Kendall SD, Counter CM. Abstract 2584: eNOS as a therapeutic target in pancreatic cancer Cancer Research. 71: 2584-2584. DOI: 10.1158/1538-7445.Am2011-2584 |
0.344 |
|
| 2010 |
Zipfel PA, Brady DC, Kashatus DF, Ancrile BD, Tyler DS, Counter CM. Ral activation promotes melanomagenesis. Oncogene. 29: 4859-64. PMID 20562921 DOI: 10.1038/Onc.2010.224 |
0.465 |
|
| 2010 |
Vignola MJ, Kashatus DF, Taylor GA, Counter CM, Valdivia RH. cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis. The Journal of Biological Chemistry. 285: 21625-35. PMID 20452986 DOI: 10.1074/Jbc.M110.103010 |
0.388 |
|
| 2010 |
Issaq SH, Lim KH, Counter CM. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis. Molecular Cancer Research : McR. 8: 223-31. PMID 20145037 DOI: 10.1158/1541-7786.Mcr-09-0189 |
0.435 |
|
| 2010 |
Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, Counter CM. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Molecular and Cellular Biology. 30: 508-23. PMID 19901077 DOI: 10.1128/Mcb.00916-08 |
0.424 |
|
| 2010 |
Petersen TH, Hitchcock T, Muto A, Calle EA, Zhao L, Gong Z, Gui L, Dardik A, Bowles DE, Counter CM, Niklason LE. Utility of telomerase-pot1 fusion protein in vascular tissue engineering. Cell Transplantation. 19: 79-87. PMID 19878625 DOI: 10.3727/096368909X478650 |
0.415 |
|
| 2009 |
O'Hayer KM, Brady DC, Counter CM. ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis. 30: 1841-7. PMID 19805574 DOI: 10.1093/Carcin/Bgp198 |
0.4 |
|
| 2009 |
Kendellen MF, Barrientos KS, Counter CM. POT1 association with TRF2 regulates telomere length. Molecular and Cellular Biology. 29: 5611-9. PMID 19651898 DOI: 10.1128/Mcb.00286-09 |
0.379 |
|
| 2008 |
Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Research. 68: 9583-8. PMID 19047133 DOI: 10.1158/0008-5472.Can-07-6178 |
0.454 |
|
| 2008 |
Schook LB, Kuzmuk K, Adam S, Rund L, Chen K, Rogatcheva M, Mazur M, Pollock C, Counter C. DNA-based animal models of human disease: From genotype to phenotype Developments in Biologicals. 132: 15-25. PMID 18817282 DOI: 10.1159/000317140 |
0.349 |
|
| 2008 |
Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Research. 68: 7561-9. PMID 18794144 DOI: 10.1158/0008-5472.Can-08-0188 |
0.387 |
|
| 2008 |
Freibaum BD, Counter CM. The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2. The Journal of Biological Chemistry. 283: 23671-6. PMID 18593705 DOI: 10.1074/Jbc.M800388200 |
0.331 |
|
| 2008 |
Tomlinson RL, Abreu EB, Ziegler T, Ly H, Counter CM, Terns RM, Terns MP. Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells. Molecular Biology of the Cell. 19: 3793-800. PMID 18562689 DOI: 10.1091/Mbc.E08-02-0184 |
0.444 |
|
| 2008 |
Linardic CM, Counter CM. Genetic modeling of Ras-induced human rhabdomyosarcoma. Methods in Enzymology. 438: 419-27. PMID 18413264 DOI: 10.1016/S0076-6879(07)38028-2 |
0.435 |
|
| 2008 |
Adam SJ, Counter CM. A method to generate genetically defined tumors in pigs. Methods in Enzymology. 439: 39-51. PMID 18374155 DOI: 10.1016/S0076-6879(07)00404-1 |
0.328 |
|
| 2008 |
Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 452: 646-9. PMID 18344980 DOI: 10.1038/Nature06778 |
0.433 |
|
| 2008 |
Ancrile BB, O'Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Molecular Interventions. 8: 22-7. PMID 18332481 DOI: 10.1124/Mi.8.1.6 |
0.41 |
|
| 2008 |
Etheridge KT, Compton SA, Barrientos KS, Ozgur S, Griffith JD, Counter CM. Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation. The Journal of Biological Chemistry. 283: 6935-41. PMID 18178559 DOI: 10.1074/Jbc.M708711200 |
0.348 |
|
| 2007 |
Rogatcheva MB, Fritz KL, Rund LA, Pollock CB, Beever JE, Counter CM, Schook LB. Characterization of the porcine ATM gene: towards the generation of a novel non-murine animal model for Ataxia-Telangiectasia. Gene. 405: 27-35. PMID 17933474 DOI: 10.1016/J.Gene.2007.08.014 |
0.405 |
|
| 2007 |
Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes & Development. 21: 1714-9. PMID 17639077 DOI: 10.1101/Gad.1549407 |
0.337 |
|
| 2007 |
Linardic CM, Naini S, Herndon JE, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Research. 67: 6691-9. PMID 17638879 DOI: 10.1158/0008-5472.Can-06-3210 |
0.421 |
|
| 2007 |
Adam SJ, Rund LA, Kuzmuk KN, Zachary JF, Schook LB, Counter CM. Genetic induction of tumorigenesis in swine. Oncogene. 26: 1038-45. PMID 16964292 DOI: 10.1038/Sj.Onc.1209892 |
0.429 |
|
| 2006 |
Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Current Biology : Cb. 16: 2385-94. PMID 17174914 DOI: 10.1016/J.Cub.2006.10.023 |
0.484 |
|
| 2006 |
O'Hayer KM, Counter CM. A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. Methods in Enzymology. 407: 637-47. PMID 16757358 DOI: 10.1016/S0076-6879(05)07050-3 |
0.479 |
|
| 2006 |
Baines AT, Lim KH, Shields JM, Lambert JM, Counter CM, Der CJ, Cox AD. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods in Enzymology. 407: 556-74. PMID 16757353 DOI: 10.1016/S0076-6879(05)07045-X |
0.458 |
|
| 2006 |
Kendall SD, Adam SJ, Counter CM. Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle (Georgetown, Tex.). 5: 1074-9. PMID 16687931 DOI: 10.4161/Cc.5.10.2734 |
0.432 |
|
| 2006 |
Freibaum BD, Counter CM. hSnm1B is a novel telomere-associated protein. The Journal of Biological Chemistry. 281: 15033-6. PMID 16606622 DOI: 10.1074/Jbc.C600038200 |
0.31 |
|
| 2005 |
Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell. 8: 381-92. PMID 16286246 DOI: 10.1016/J.Ccr.2005.10.014 |
0.406 |
|
| 2005 |
Kendall SD, Linardic CM, Adam SJ, Counter CM. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Research. 65: 9824-8. PMID 16267004 DOI: 10.1158/0008-5472.Can-05-1543 |
0.478 |
|
| 2005 |
Poh M, Boyer M, Solan A, Dahl SL, Pedrotty D, Banik SS, McKee JA, Klinger RY, Counter CM, Niklason LE. Blood vessels engineered from human cells. Lancet. 365: 2122-4. PMID 15964449 DOI: 10.1016/S0140-6736(05)66735-9 |
0.311 |
|
| 2005 |
Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell. 7: 533-45. PMID 15950903 DOI: 10.1016/J.Ccr.2005.04.030 |
0.507 |
|
| 2005 |
Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer Research. 65: 4490-5. PMID 15930263 DOI: 10.1158/0008-5472.Can-04-3194 |
0.365 |
|
| 2005 |
Niklason LE, Counter CM. Blood vessels engineered from human cells – Authors' reply The Lancet. 366: 892-893. DOI: 10.1016/S0140-6736(05)67313-8 |
0.301 |
|
| 2004 |
Veldman T, Etheridge KT, Counter CM. Loss of hPot1 function leads to telomere instability and a cut-like phenotype. Current Biology : Cb. 14: 2264-70. PMID 15620654 DOI: 10.1016/J.Cub.2004.12.031 |
0.412 |
|
| 2004 |
Swanson KS, Mazur MJ, Vashisht K, Rund LA, Beever JE, Counter CM, Schook LB. Genomics and clinical medicine: rationale for creating and effectively evaluating animal models. Experimental Biology and Medicine (Maywood, N.J.). 229: 866-75. PMID 15388881 DOI: 10.1177/153537020422900902 |
0.304 |
|
| 2004 |
Banik SS, Counter CM. Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. The Journal of Biological Chemistry. 279: 51745-8. PMID 15381700 DOI: 10.1074/Jbc.M408131200 |
0.413 |
|
| 2004 |
Lim KH, Counter CM. Leveling the playing field. Molecular Cell. 15: 491-2. PMID 15327763 DOI: 10.1016/J.Molcel.2004.08.014 |
0.413 |
|
| 2004 |
Armbruster BN, Linardic CM, Veldman T, Bansal NP, Downie DL, Counter CM. Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1. Molecular and Cellular Biology. 24: 3552-61. PMID 15060173 DOI: 10.1128/Mcb.24.8.3552-3561.2004 |
0.373 |
|
| 2004 |
Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR, Sears R. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biology. 6: 308-18. PMID 15048125 DOI: 10.1038/Ncb1110 |
0.527 |
|
| 2003 |
Guo C, Armbruster BN, Price DT, Counter CM. In vivo regulation of hTERT expression and telomerase activity by androgen. The Journal of Urology. 170: 615-8. PMID 12853842 DOI: 10.1097/01.Ju.0000074653.22766.C8 |
0.354 |
|
| 2003 |
McKee JA, Banik SS, Boyer MJ, Hamad NM, Lawson JH, Niklason LE, Counter CM. Human arteries engineered in vitro. Embo Reports. 4: 633-8. PMID 12776184 DOI: 10.1038/Sj.Embor.Embor847 |
0.345 |
|
| 2003 |
Armbruster BN, Etheridge KT, Broccoli D, Counter CM. Putative telomere-recruiting domain in the catalytic subunit of human telomerase. Molecular and Cellular Biology. 23: 3237-46. PMID 12697823 DOI: 10.1128/Mcb.23.9.3237-3246.2003 |
0.419 |
|
| 2003 |
Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. The Journal of Biological Chemistry. 278: 15951-7. PMID 12590137 DOI: 10.1074/Jbc.M211498200 |
0.394 |
|
| 2002 |
Hamad NM, Banik SS, Counter CM. Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene. 21: 7121-5. PMID 12370834 DOI: 10.1038/Sj.Onc.1205860 |
0.471 |
|
| 2002 |
Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, Counter CM. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes & Development. 16: 2045-57. PMID 12183360 DOI: 10.1101/Gad.993902 |
0.429 |
|
| 2002 |
Banik SS, Guo C, Smith AC, Margolis SS, Richardson DA, Tirado CA, Counter CM. C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity. Molecular and Cellular Biology. 22: 6234-46. PMID 12167716 DOI: 10.1128/Mcb.22.17.6234-6246.2002 |
0.435 |
|
| 2002 |
Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, Wang CY. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nature Biotechnology. 20: 587-91. PMID 12042862 DOI: 10.1038/Nbt0602-587 |
0.305 |
|
| 2002 |
Etheridge KT, Banik SS, Armbruster BN, Zhu Y, Terns RM, Terns MP, Counter CM. The nucleolar localization domain of the catalytic subunit of human telomerase. The Journal of Biological Chemistry. 277: 24764-70. PMID 11956201 DOI: 10.1074/Jbc.M201227200 |
0.364 |
|
| 2001 |
Armbruster BN, Banik SS, Guo C, Smith AC, Counter CM. N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo. Molecular and Cellular Biology. 21: 7775-86. PMID 11604512 DOI: 10.1128/Mcb.21.22.7775-7786.2001 |
0.401 |
|
| 2001 |
Guo C, Geverd D, Liao R, Hamad N, Counter CM, Price DT. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. The Journal of Urology. 166: 694-8. PMID 11458119 DOI: 10.1016/S0022-5347(05)66045-4 |
0.428 |
|
| 2001 |
Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Research. 61: 3556-60. PMID 11325817 |
0.325 |
|
| 2001 |
Elconin JH, Hamad NM, Counter CM. H-ras may transform human cells through a different mechanism than previously thought International Journal of Radiation Oncology Biology Physics. 51: 185-186. DOI: 10.1016/S0360-3016(01)02160-5 |
0.383 |
|
| 1999 |
Hu PPC, Shen X, Huang D, Liu Y, Counter C, Wang XF. The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-β Journal of Biological Chemistry. 274: 35381-35387. PMID 10585406 DOI: 10.1074/Jbc.274.50.35381 |
0.301 |
|
| 1999 |
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 400: 464-8. PMID 10440377 DOI: 10.1038/22780 |
0.678 |
|
| 1998 |
Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proceedings of the National Academy of Sciences of the United States of America. 95: 14723-8. PMID 9843956 DOI: 10.1073/Pnas.95.25.14723 |
0.674 |
|
| 1998 |
Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nature Genetics. 19: 182-6. PMID 9620778 DOI: 10.1038/554 |
0.621 |
|
| 1998 |
Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 16: 1217-22. PMID 9528864 DOI: 10.1038/Sj.Onc.1201882 |
0.679 |
|
| 1997 |
Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 90: 785-95. PMID 9288757 DOI: 10.1016/S0092-8674(00)80538-3 |
0.666 |
|
| 1997 |
Counter CM, Meyerson M, Eaton EN, Weinberg RA. The catalytic subunit of yeast telomerase. Proceedings of the National Academy of Sciences of the United States of America. 94: 9202-7. PMID 9256460 DOI: 10.1073/Pnas.94.17.9202 |
0.602 |
|
| 1996 |
Counter CM. The roles of telomeres and telomerase in cell life span. Mutation Research. 366: 45-63. PMID 8921986 DOI: 10.1016/S0165-1110(96)90006-8 |
0.412 |
|
| 1995 |
Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 85: 2315-20. PMID 7727765 DOI: 10.1182/Blood.V85.9.2315.Bloodjournal8592315 |
0.437 |
|
| 1994 |
Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 91: 2900-4. PMID 8159676 DOI: 10.1073/Pnas.91.8.2900 |
0.45 |
|
| 1994 |
Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. Journal of Virology. 68: 3410-4. PMID 8151802 DOI: 10.1128/Jvi.68.5.3410-3414.1994 |
0.402 |
|
| 1994 |
Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW. Telomerase, cell immortality, and cancer. Cold Spring Harbor Symposia On Quantitative Biology. 59: 307-15. PMID 7587082 DOI: 10.1101/Sqb.1994.059.01.035 |
0.382 |
|
| 1992 |
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. The Embo Journal. 11: 1921-9. PMID 1582420 DOI: 10.1002/J.1460-2075.1992.Tb05245.X |
0.39 |
|
| Show low-probability matches. |